TGTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
259.9M
+8.2%
240.3M
+17.3%
204.9M
+6.4%
192.6M
+19.1%
161.7M
Cost of Revenue
42.1M
+2.1%
41.2M
+22.9%
33.5M
-12.1%
38.1M
+35.8%
28.1M
Gross Profit
217.9M
+9.4%
199.1M
+16.2%
171.4M
+11.0%
154.4M
+15.6%
133.6M
Operating Expenses
132.0M
-25.6%
177.5M
+29.9%
136.6M
+31.4%
103.9M
-0.3%
104.3M
R&D
43.7M
-49.9%
87.3M
+100.5%
43.5M
+77.1%
24.6M
-30.9%
35.5M
SG&A
88.2M
-2.2%
90.2M
+352.1%
19.9M
-30.3%
28.6M
-58.3%
68.7M
Operating Income
85.9M
+296.3%
21.7M
-37.7%
34.8M
-31.1%
50.5M
+72.0%
29.4M
EBITDA
86.0M
+295.7%
21.7M
-37.6%
34.8M
-30.9%
50.4M
+71.5%
29.4M
Net Income
55.5M
+612.8%
7.8M
-60.7%
19.8M
-14.2%
23.0M
-94.1%
390.9M
EPS (Basic)
$0.39
+680.0%
$0.05
-64.3%
$0.14
-17.6%
$0.17
-93.7%
$2.69
EPS (Diluted)
$0.35
+600.0%
$0.05
-58.3%
$0.12
-14.3%
$0.14
-94.2%
$2.43
Shares (Diluted)
155.9M
-0.9%
157.3M
-1.7%
160.1M
+0.5%
159.3M
-1.0%
161.0M
TG Therapeutics (TGTX) — Financials